Alzheon, Inc. announced that it has appointed Gino Santini to its Board of Directors. Mr. Santini retired from a long and distinguished career at Eli Lilly in 2010. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, President of the Women?s Health Franchise and President of U.S. Operations.

Mr. Santini capped his career at Eli Lilly as a member of the company?s executive committee and as Senior Vice President of Corporate Strategy and Business Development. Mr. Santini currently serves on the Boards of Directors of Intercept Pharmaceuticals and Collegium Pharmaceuticals. He previously served on the boards of SORIN SpA, Vitae Pharmaceuticals, Horizon Therapeutics, and AMAG Pharmaceuticals, until their acquisitions, and of Intarcia Therapeutics and Allena Pharmaceuticals.

Mr. Santini is fluent in four languages and holds an undergraduate degree in mechanical engineering from the University of Bologna and an MBA from the University of Rochester.